268 related articles for article (PubMed ID: 23748464)
1. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
[TBL] [Abstract][Full Text] [Related]
2. Adult medulloblastoma: multiagent chemotherapy.
Greenberg HS; Chamberlain MC; Glantz MJ; Wang S
Neuro Oncol; 2001 Jan; 3(1):29-34. PubMed ID: 11305414
[TBL] [Abstract][Full Text] [Related]
3. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
[TBL] [Abstract][Full Text] [Related]
5. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
7. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE
J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276
[TBL] [Abstract][Full Text] [Related]
10. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
11. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Lefkowitz IB; Packer RJ; Siegel KR; Sutton LN; Schut L; Evans AE
Cancer; 1990 Feb; 65(3):412-7. PubMed ID: 2153428
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
13. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Chamberlain MC; Glantz MJ
Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
[TBL] [Abstract][Full Text] [Related]
14. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
Geyer JR; Sposto R; Jennings M; Boyett JM; Axtell RA; Breiger D; Broxson E; Donahue B; Finlay JL; Goldwein JW; Heier LA; Johnson D; Mazewski C; Miller DC; Packer R; Puccetti D; Radcliffe J; Tao ML; Shiminski-Maher T;
J Clin Oncol; 2005 Oct; 23(30):7621-31. PubMed ID: 16234523
[TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors.
Allen JC; Donahue B; DaRosso R; Nirenberg A
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038
[TBL] [Abstract][Full Text] [Related]
16. Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Massimino M; Casanova M; Polastri D; Biassoni V; Modena P; Pecori E; Schiavello E; De Pava MV; Indini A; Rampini P; Bauer D; Catania S; Podda M; Gandola L
Childs Nerv Syst; 2013 Jul; 29(7):1107-12. PubMed ID: 23595805
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
18. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
Al-Hader AA; Jain A; Al-Nasrallah N; Einhorn LH
Am J Clin Oncol; 2015 Aug; 38(4):364-6. PubMed ID: 23799289
[TBL] [Abstract][Full Text] [Related]
19. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
